Abstract
Following the paradigm set by STI571, protein tyrosine kinase inhibitors are emerging as a promising class of drugs, capable of modulating intracellular signaling and demonstrating therapeutic potential for the treatment of proliferative diseases. Although the majority of chronic phase CML patients treated with STI571 respond, some patients, especially those with more advanced disease, relapse. This article reviews the reasons for relapse and, in particular, analyses resistance resulting from Bcr-Abl tyrosine kinase domain mutations at the molecular level. Arguments are based upon the structure of the STI571-Abl complex, which is compared to the crystal structures of PD173955-Abl and PD180970-Abl, which bind to the kinase differently. Strategies to potentially circumvent or overcome resistance are discussed.
Keywords: Imatinib, protein tyrosine kinase, STI571-Abl
Mini-Reviews in Medicinal Chemistry
Title: Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment
Volume: 4 Issue: 3
Author(s): Sandra W. Cowan-Jacob, Valerie Guez, Gabriele Fendrich, James D. Griffin, Doriano Fabbro, Pascal Furet, Janis Liebetanz, Jurgen Mestan and Paul W. Manley
Affiliation:
Keywords: Imatinib, protein tyrosine kinase, STI571-Abl
Abstract: Following the paradigm set by STI571, protein tyrosine kinase inhibitors are emerging as a promising class of drugs, capable of modulating intracellular signaling and demonstrating therapeutic potential for the treatment of proliferative diseases. Although the majority of chronic phase CML patients treated with STI571 respond, some patients, especially those with more advanced disease, relapse. This article reviews the reasons for relapse and, in particular, analyses resistance resulting from Bcr-Abl tyrosine kinase domain mutations at the molecular level. Arguments are based upon the structure of the STI571-Abl complex, which is compared to the crystal structures of PD173955-Abl and PD180970-Abl, which bind to the kinase differently. Strategies to potentially circumvent or overcome resistance are discussed.
Export Options
About this article
Cite this article as:
Cowan-Jacob W. Sandra, Guez Valerie, Fendrich Gabriele, Griffin D. James, Fabbro Doriano, Furet Pascal, Liebetanz Janis, Mestan Jurgen and Manley W. Paul, Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment, Mini-Reviews in Medicinal Chemistry 2004; 4 (3) . https://dx.doi.org/10.2174/1389557043487321
DOI https://dx.doi.org/10.2174/1389557043487321 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid-based Nanocarriers Loaded with Taxanes for the Management of
Breast Cancer: Promises and Challenges
Current Drug Targets The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate
Letters in Drug Design & Discovery Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Current Pharmaceutical Biotechnology Retroviral Protein Transfer: Falling Apart to Make an Impact
Current Gene Therapy Recent Advances in the New Generation Taxane Anticancer Agents
Medicinal Chemistry Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology CAM Use in Pediatric Oncology
Current Pediatric Reviews Maximizing Baculovirus-Mediated Foreign Proteins Expression in Mammalian Cells
Current Gene Therapy Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine
Current Drug Targets Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Amyotrophic Lateral Sclerosis and Excitotoxicity: From Pathological Mechanism to Therapeutic Target
CNS & Neurological Disorders - Drug Targets Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach
Mini-Reviews in Medicinal Chemistry